Winship Cancer Institute of Emory University | Strategic Alliance Partners

The data are part of the largest reported cohorts of consecutive and uniformly treated real-world patients with newly diagnosed multiple myeloma.

Jean L. Koff, MD, MS, discusses factors that influence treatment decision-making for patients with MCL in the frontline and maintenance settings.

Oncology experts share their key takeaways in genitourinary cancers and recent updates from the 2024 ESMO Congress.

Jacob E. Berchuck, MD, discusses the use of a novel epigenomic liquid biopsy platform to noninvasively detect PSMA expression in mCRPC.

The relapsed/refractory multiple myeloma experts conclude by highlighting current unmet needs in the field and sharing valuable clinical pearls to guide practice and improve patient outcomes.

Sagar Lonial, MD, FACP, discusses the broad impact of the CoMMpass study on understanding the molecular underpinnings of multiple myeloma.

The key opinion leaders provide essential insights and recommendations for community oncologists to enhance and optimize treatment strategies for their patients with relapsed/refractory multiple myeloma.

The experts in relapsed/refractory multiple myeloma care outline their treatment sequencing strategies for patients who have already received T-cell engaging therapies.

Sagar Lonial, MD, FACP, discusses unique subtypes of multiple myeloma identified through the CoMMpass study.

Sagar Lonial, MD, FACP, discusses findings from the CoMMpass trial, which identified high-risk genetic markers in patients with myeloma.

Kevin Kalinsky, MD, MS, discusses AMH levels and responses in premenopausal HR+/HER2–, node-positive breast cancer.

In a forward-looking discussion, Ticiana Leal, MD; Anne Chiang, MD, PhD; Afshin Dowlati, MD; and Tarita O. Thomas, MD, PhD, offer their concluding insights on the evolving landscape of clinical trials and the future directions of small cell lung cancer (SCLC) treatment, highlighting promising areas of research and potential breakthroughs that may shape the management of this challenging disease in the years to come.

Experts delve into the DAREON-8 Phase 1 clinical trial, assessing the potential impact of incorporating the study into the current treatment algorithm for small cell lung cancer (SCLC).

Medical experts review the Ideate-Lung02 phase 3 clinical trial, exploring the potential for ifinatamab to elicit durable responses in patients with advanced small cell lung cancer (SCLC), and discussing the implications of these findings for the future treatment landscape of SCLC.

In a detailed analysis, key opinion leaders (KOLs) review the results of the DELLphi-301 Phase 2 clinical trial, assessing the efficacy of platinum-based chemotherapy in the treatment of small cell lung cancer (SCLC) and its impact on overall survival outcomes for patients enrolled in the study.

In a focused discussion, Anne Chiang, MD, PhD, explores the sequencing of later-line therapies for limited-stage small cell lung cancer (LS-SCLC), emphasizing key factors to consider when making treatment decisions for patients who have progressed on initial therapy.

As the lung cancer paradigm continues to advance, increasingly effective therapies are under development for previously underserved disease subtypes.

Anthony M. Hunter, MD, discusses challenges associated with ruxolitinib-based toxicities in patients with myelofibrosis.

Anthony M. Hunter, MD, discusses the evolution of pathology in myelofibrosis based on outcomes from clinical trials.

Kevin Kalinsky, MD, MS, discusses the outcomes of the postMONARCH study in patients with HR+/HER2– breast cancer following disease progression.

Suresh S. Ramalingam, MD, FACP, FASCO, and Chandler H. Park, MD, FACP, discuss updates in non–small cell lung cancer at the 2024 ASCO Annual Meeting.

Kevin Kalinsky, MD, MS, discusses the utility of the postMONARCH trial regimen in hormone receptor–positive/HER2-negative advanced breast cancer.

Anthony Hunter, MD, discusses JAK inhibitor selection in myelofibrosis in the first line and beyond.

Suresh S. Ramalingam, MD, FACP, FASCO, discusses findings with osimertinib after definitive chemoradiotherapy in unresectable EGFR-mutated NSCLC.

Abemaciclib plus fulvestrant improved PFS vs fulvestrant alone in select patients with hormone receptor–positive/HER2-negative advanced breast cancer.

Vikram M. Narayan, MD, discusses the utility of nadofaragene firadenovec in patients with non–muscle-invasive bladder cancer and beyond.

Vikram M. Narayan, MD, discusses the final 5-year analysis of a phase 3 trial of nadofaragene firadenovec in patients with BCG-unresponsive NMIBC.

Jean L. Koff, MD, MS, discusses the toxicities associated with pirtobrutinib in the BRUIN trial for mantle cell lymphoma.

As investigators parse out the mechanism of action of nadofaragene firadenovec, additional gene therapies are under development in BCG-unresponsive NMIBC.

Jean L. Koff, MD, MS, discusses key considerations in the choice of BTK inhibitors for frontline and maintenance treatment in MCL.